Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy-Reference-Cited by-同舟云学术

Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy

Published:2011-05-17 Issue:2 Volume:128 Page:437-445
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Lalisang R. I.,Erdkamp F. L. G.,Rodenburg C. J.,Knibbeler-van Rossum C. T. A. M.,Nortier J. W. R.,van Bochove A.,Slee P. H. Th. J.,Voest E. E.,Wils J. A.,Wals J.,Loosveld O. J. L.,Smals A. E. M.,Blijham G. H.,Tjan-Heijnen V. C. G.,Schouten H. C.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-011-1558-3.pdf

Reference25 articles.

1. A’Hern RP, Smith IE, Ebbs SR (1993) Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer 67:801–805

2. Crown J, Diéras V, Kaufmann M, von Minckwitz G et al (2002) Chemotherapy for metastatic breast cancer—report of a European expert panel. Lancet Oncol 3:719–726

3. Gianni L, Munzone E, Capri G et al (1995) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688–2699

4. Gehl J, Boesgaard M, Paaske T et al (1996) Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 7:687–693

5. Jain KK, Casper ES, Geller NL et al (1985) A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 3:818–826

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of cardiotoxicity of anthracycline‐containing chemotherapy regimens in patients with bone and soft tissue sarcomas: A study of the FDA adverse event reporting system joint single‐center real‐world experience;Cancer Medicine;2023-12

2. Cardiovascular and Central Nervous System Toxicity by Anticancer Drugs in Breast Cancer Patients;Brain and Heart Dynamics;2020

3. Cardiovascular and Central Nervous System Toxicity by Anticancer Drugs in Breast Cancer Patients;Brain and Heart Dynamics;2019-11-08

4. Dose intensity in anthracycline-based chemotherapy for metastatic breast cancer: mature results of the randomised clinical trial ANZ 9311;Breast Cancer Research and Treatment;2019-04-26

5. Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective;Clinical Breast Cancer;2016-04